{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:26:48Z","timestamp":1778707608219,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ygyno.2017.07.137","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T08:30:16Z","timestamp":1501576216000},"page":"41-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer"],"prefix":"10.1016","volume":"147","author":[{"given":"Nicole D.","family":"Fleming","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celestine","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Bhosale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark F.","family":"Munsell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.07.137_bb0005","series-title":"Cancer Facts & Figures","author":"American Cancer Society","year":"2017"},{"key":"10.1016\/j.ygyno.2017.07.137_bb0010","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"Du Bois","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0015","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0025","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2017.07.137_bb0030","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomized, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0035","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0040","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0045","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1525-1438.2001.011004295.x","article-title":"Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects","volume":"11","author":"Wu","year":"2001","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.07.137_bb0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00280-007-0466-z","article-title":"Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase II study of the NOGGO","volume":"61","author":"Sehouli","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.critrevonc.2007.12.005","article-title":"A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian Cancer (MITO-5) study","volume":"66","author":"Pignata","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/gyno.2002.6859","article-title":"Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer","volume":"88","author":"Havrilesky","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0065","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1016\/j.ejca.2013.08.002","article-title":"Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer","volume":"49","author":"Gonzalez-Martin","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.07.137_bb0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid, and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(94)90187-2","article-title":"The implications of angiogenesis for the biology and therapy of cancer metastasis","volume":"79","author":"Fidler","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2017.07.137_bb0080","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0085","first-page":"3369","article-title":"The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors","volume":"61","author":"Sweeney","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0090","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/sj.bjc.6601005","article-title":"Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11","volume":"88","author":"Wildiers","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.07.137_bb0095","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.07.137_bb0105","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X","article-title":"Optimal flexible designs in phase II clinical trials","volume":"17","author":"Chen","year":"1998","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2307\/2533377","article-title":"Practical Bayesian guidelines for phase IIB clinical trials","volume":"50","author":"Thall","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2017.07.137_bb0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0125","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0130","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.cgt.7700534","article-title":"Antitumor effect of secreted Flt3-ligand can act at distant tumor sites in a murine model of head and neck cancer","volume":"10","author":"Dong","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ygyno.2017.07.137_bb0135","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4161\/cbt.1.5.161","article-title":"Flt-3 ligand: a potent dendritic cell stimulator and novel antitumor agent","volume":"1","author":"Dong","year":"2002","journal-title":"Cancer Biol Ther"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817311770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817311770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T22:20:21Z","timestamp":1719354021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817311770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0090825817311770"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.07.137","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.07.137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}